- Home
- REBN vs BCDA Comparison
REBN vs BCDA Comparison
Compare REBN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- BCDA
- Stock Information
- Founded
- REBN 2015
- BCDA N/A
- Country
- REBN United States
- BCDA United States
- Employees
- REBN N/A
- BCDA N/A
- Industry
- REBN Restaurants
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- BCDA Health Care
- Exchange
- REBN Nasdaq
- BCDA Nasdaq
- Market Cap
- REBN 13.5M
- BCDA 9.4M
- IPO Year
- REBN 2022
- BCDA N/A
- Fundamental
- Price
- REBN $2.77
- BCDA $2.44
- Analyst Decision
- REBN
- BCDA Strong Buy
- Analyst Count
- REBN 0
- BCDA 1
- Target Price
- REBN N/A
- BCDA $25.00
- AVG Volume (30 Days)
- REBN 87.9K
- BCDA 104.7K
- Earning Date
- REBN 03-31-2025
- BCDA 05-14-2025
- Dividend Yield
- REBN N/A
- BCDA N/A
- EPS Growth
- REBN N/A
- BCDA N/A
- EPS
- REBN N/A
- BCDA N/A
- Revenue
- REBN $5,928,533.00
- BCDA $3,000.00
- Revenue This Year
- REBN $335.98
- BCDA N/A
- Revenue Next Year
- REBN N/A
- BCDA N/A
- P/E Ratio
- REBN N/A
- BCDA N/A
- Revenue Growth
- REBN 7.63
- BCDA N/A
- 52 Week Low
- REBN $1.03
- BCDA $1.63
- 52 Week High
- REBN $8.80
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- REBN 45.20
- BCDA 48.85
- Support Level
- REBN $2.46
- BCDA $2.40
- Resistance Level
- REBN $3.45
- BCDA $2.92
- Average True Range (ATR)
- REBN 0.24
- BCDA 0.31
- MACD
- REBN 0.07
- BCDA -0.02
- Stochastic Oscillator
- REBN 34.62
- BCDA 16.48
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).